General Information of Drug (ID: DM1KZW0)

Drug Name
MGC018 Drug Info
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Cross-matching ID
TTD Drug ID
DM1KZW0

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Clinical Trial Drug(s)
Drug(s) Targeting B7 homolog 3 (CD276)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Omburtamab I-131 DMPDA17 Neuroblastoma 2D11.2 Phase 2/3 [3]
131 I-omburtamab DM12UX6 Brain and central nervous system tumour 2A00.11 Phase 2/3 [4]
Omburtamab DMTIESG Neuroblastoma 2D11.2 Phase 2/3 [5]
Enoblituzumab DMDS20X Prostate cancer 2C82.0 Phase 2 [6]
TAK-280 DM08RE5 Aggressive cancer 2A00-2F9Z Phase 2 [7]
DS-7300 DMK4VY9 Solid tumour/cancer 2A00-2F9Z Phase 1/2 [8]
Omburtamab I-124 DMPLBDF Glioma 2A00.0 Phase 1/2 [3]
MGD009 DME4B8I Solid tumour/cancer 2A00-2F9Z Phase 1 [6]
MGA271 DM2PVLH Metastatic cancer 2D50-2E2Z Phase 1 [9]
124I-8H9 DM5ZC0E Glioblastoma multiforme 2A00.0 Phase 1 [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
B7 homolog 3 (CD276) TT6CQUM CD276_HUMAN Not Available [2]

References

1 ClinicalTrials.gov (NCT03729596) MGC018 With or Without MGA012 in Advanced Solid Tumors. U.S. National Institutes of Health.
2 Clinical pipeline report, company report or official report of MacroGenics.
3 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
4 IntraOmmaya compartmental radioimmunotherapy using 131 I-omburtamab-pharmacokinetic modeling to optimize therapeutic index. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1166-1177.
5 Mast cell proliferation in the cerebrospinal fluid after intraventricular administration of anti-B7H3 immunotherapy. Cancer Immunol Immunother. 2021 Feb 3.
6 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
7 ClinicalTrials.gov (NCT05220098) A Phase 1/2, First-in-Human, Open-Label, Dose-Escalation Study of TAK-280 in Patients With Unresectable Locally Advanced or Metastatic Cancer. U.S.National Institutes of Health.
8 Clinical pipeline report, company report or official report of Daiichi Sankyo.
9 T Cell Coinhibition and Immunotherapy in Human Breast Cancer. Discov Med. 2012 October; 14(77): 229-236.
10 National Cancer Institute Drug Dictionary (drug id 722029).